Li Xinyu, Huang Zhihao, Lau Cia-Hin, Li Jiaqi, Zou Minghai, Wu Weidong, Chen Xiaoqing, Li Jiahui, Huang Yumei, Wang Tao, Li Yulin, Xu Meijing, Huang Xiaojun, Zhu Haibao, Yang Chunkang
College of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, Fujian, China.
Department of Gastrointestinal Surgery, The First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, Fujian, China.
Anal Methods. 2025 Jan 23;17(4):823-833. doi: 10.1039/d4ay01695e.
MicroRNA (miRNA) is a promising biomarker for the early diagnosis of pancreatic cancer. To enable sensitive and reliable miRNA detection, we have developed a one-pot isothermal CRISPR/Dx detection system by combining rolling circle amplification (RCA) and CRISPR/Cas12a. RCA and CRISPR/Cas12a reactions are carried out in a single closed tube, bypassing the transferring step. We demonstrate the feasibility of our one-pot CRISPR/Dx system in detecting pancreatic cancer by targeting miR-25, miR-191, miR-205, and miR-1246. When applied to fluorescence- and lateral flow strip paper-based detection platforms, our one-pot CRISPR/Dx system detects synthetic miR-25 at a LOD of 6.60 fM and 500 fM, respectively. It has high targeting specificity, as shown by its ability to discriminate miR-25 with a single-base mutation and highly homologous miRNA species. It is also successfully generalized to detect other pancreatic cancer-associated miRNAs, including miR-191, miR-205, and miR-1246. Importantly, our one-pot CRISPR/Dx system enables specific and sensitive detection of endogenous miR-25 in the human pancreatic cancer cell line PANC-1. We have successfully developed a one-pot isothermal CRISPR/Dx system for detecting miRNA with high specificity and sensitivity. It is highly flexible and economical, as a common crRNA can detect different miRNAs and only requires minor modifications to the locking padlock probe. Therefore, it can potentially be translated into clinical settings and POCT for the diagnosis of various human cancers.
微小RNA(miRNA)是一种很有前景的胰腺癌早期诊断生物标志物。为了实现灵敏且可靠的miRNA检测,我们通过结合滚环扩增(RCA)和CRISPR/Cas12a开发了一种单管等温CRISPR/Dx检测系统。RCA反应和CRISPR/Cas12a反应在单个封闭管中进行,绕过了转移步骤。我们通过靶向miR-25、miR-191、miR-205和miR-1246,证明了我们的单管CRISPR/Dx系统在检测胰腺癌方面的可行性。当应用于基于荧光和侧流试纸条的检测平台时,我们的单管CRISPR/Dx系统分别以6.60 fM和500 fM的检测限检测合成的miR-25。它具有高靶向特异性,能够区分具有单碱基突变的miR-25和高度同源的miRNA物种。它还成功推广用于检测其他胰腺癌相关miRNA,包括miR-191、miR-205和miR-1246。重要的是,我们的单管CRISPR/Dx系统能够特异性且灵敏地检测人胰腺癌细胞系PANC-1中的内源性miR-25。我们成功开发了一种用于检测miRNA的具有高特异性和灵敏度的单管等温CRISPR/Dx系统。它具有高度灵活性和经济性,因为一种通用的crRNA可以检测不同的miRNA,并且仅需对锁式锁探针进行微小修改。因此,它有可能转化为临床应用和即时检测(POCT)用于各种人类癌症的诊断。